The Effect of Levagen+ (Palmitoylethanolamide) Supplementation on Symptoms of Allergic Rhinitis—A Double-Blind Placebo-Controlled Trial
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 108 adults with seasonal allergic rhinitis randomised. 101 completed.
- Dose used in the study
- 350 mg a day of Levagen+
- Duration
- 14 days
- What was measured
- Total nasal symptom score. A quality of life questionnaire. Blood markers including histamine and cytokines in a subset of 36 participants.
What the authors reported
The authors reported no significant difference between the groups in nasal symptom scores over the 14 days. In a sub-group with higher symptom scores at the start, they reported lower scores on Levagen+ at week 2. In the 36 participants with blood samples, they reported a larger fall in plasma histamine on Levagen+. Adverse events were reported only in the placebo group.
Limits of this study
The main outcome showed no difference. The sub-group result is exploratory. Blood results come from about a third of participants. The authors noted a strong placebo response and that COVID-19 lockdowns may have reduced allergen exposure. The study was funded by Gencor Pacific.
Source
Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.